CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-based therapeutics, today announced that it will give one oral presentation and two poster presentations on data from its ongoing Phase II and preclinical trials evaluating exon-skipping therapies for the treatment of Duchenne muscular dystrophy (DMD) at the International Congress of the World Muscle Society (WMS), being held from October 7-11, 2014, in Berlin, Germany. The oral presentation will include additional detail about the 144-week, 6-minute walk test (6MWT) and safety data from the Phase IIb study of eteplirsen, as well as other information including 144-week pulmonary function test results and information on individual MIP and MEP results.
Help employers find you! Check out all the jobs and post your resume.
